Transgene Biotek (BOM:526139) Net Loan

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:526139 Transgene Biotek Ltd BOM:526139
55 GF Score
Price ₹2.70
GF Value ₹4.30
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Transgene Biotek Net Loan?

Net Loan only applies to banks and insurance companies.

BOM:526139
55GF Score
Transgene Biotek Ltd BOM:526139
Net Loan is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Transgene Biotek (BOM:526139) Overvalued in 2026?

Based on GuruFocus' analysis, Transgene Biotek stock appears to be undervalued. The current stock price of ₹2.70 is trading 37.2% below its estimated GF Value™ of ₹4.30. GuruFocus considers Transgene Biotek to be Possible Value Trap.

Key valuation signals for BOM:526139:

  • Net Loan:
  • GF Value™: ₹4.30 vs. price of ₹2.70 (37.2% below fair value)
  • GF Score™: 55/100 with 4 warning signs

No single metric tells the full story. See the BOM:526139 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Transgene Biotek Business Description

Address Anrich Industrial Area, Plot No. 69 and 70, IDA Bollaram, Sangareddy District, Medak, TG, IND, 502325
Transgene Biotek Ltd is an India-based pharmaceutical research and development company focused on biotechnology-derived active pharmaceutical ingredients and finished pharmaceutical products. Its operations center on a single reporting segment, bulk drugs, where it develops and manufactures molecules using recombinant and bioprocessing technologies. The company's product portfolio includes TrabiDHA, a docosahexaenoic acid-based ingredient, along with Tracolimus and Orlistat, covering areas such as immunosuppression and weight management. Transgene Biotek serves pharmaceutical manufacturers and formulators, supplying APIs and related products primarily within India, and it generates revenue through the sale of goods and services. The company also pursues research collaborations and technology development for producing pharmaceutical ingredients, positioning itself as a supplier of specialty bulk drugs and biotech-based intermediates to the domestic pharmaceutical industry.
55GF Score

Get the complete analysis for BOM:526139

Net Loan is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2.70
Price
₹4.30
GF Value